Author + information
This article has been retracted: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy).
The prevalence of MVO was reduced in the adenosine-treated patients (45%) compared to 85% of control patients (P=0.0043). We found that the size of MVO in adenosine-treated patients was significantly reduced (0.35g) compared to 0.91 g in the control group (P=0.027). There was no statistically significant difference in TIMI flow and clinical outcomes after primary PCI.
Excel software was used to calculate the p-values. On recalculation using a newer version of the programme, the values are coming back different: Prevalence of MVO comparing adenosine to non-adenosine is now 0.15, therefore non-significant. Also the P-value for the mass of MVO in adenosine versus non-adenosine is 0.34, again non-significant.
Poster Sessions, Expo North
Sunday, March 10, 2013, 9:45 a.m.-10:30 a.m.
Session Title: ACS Therapy: No Reflow and Improving Outcomes
Abstract Category: 3. Acute Coronary Syndromes: Therapy
Presentation Number: 1214-202
- 2013 American College of Cardiology Foundation